A single course of the ANGPTL3 CRISPR/Cas9 gene editing therapy, CTX310, has reduced mean circulating ANGPTL3 by 65% at day 30 and mean TG by 63% in a Phase 1b study in patients with severe hypertriglyceridaemia (sHTG).1
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
